Ligand Pharmaceuticals Inc. (LGND) Financials
Key financial figures for Ligand Pharmaceuticals Inc. (Q3 2026).
Ligand Q3 royalty revenue rose 51% to $70.3M on the XOMA portfolio; adjusted EPS $2.67 vs FMP estimate $2.33; full-year adjusted EPS guidance raised to $9.50-$9.75. Royalty revenue grew 51% year over year to $70.3M (89% of total revenues and income), driven by the newly acquired XOMA assets plus Filspari and Ohtuvayre. Total revenues and income were $78.7M vs $115.5M a year ago, which included $53.1M of Pelthos-related income. Adjusted EPS was $2.67 (down 14% from $3.09), above the FMP estimate of $2.33; GAAP net loss was $28.5M, or $1.43 per share, on $39.5M of pre-tax investment losses and $72.6M of G&A including XOMA deal and integration costs. On the outlook: 2026: royalty revenue $225M-$250M, Captisol sales $35M-$40M, contract revenue $10M-$20M, total revenue $270M-$310M (all unchanged); adjusted earnings per diluted share about $9.50-$9.75, raised from about $9.00-$9.50. Figures are for Q3 2026, as Ligand Pharmaceuticals Incorporated reported them.
- Revenue
- $79M
- Net Income
- -$28M
- EPS
- $-1.43
- Total Assets
- $2.2B
- Operating Cash Flow
- -$28M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $79M | -$28M | -$1.43 | -20.01% | -$28M |
| Q2 FY2026 | $64M | $49M | $2.22 | 13.49% | $24M |
| Q1 FY2026 | $52M | -$13M | -$0.67 | 33.58% | $48M |
| Q4 FY2025 | $60M | $45M | $2.12 | 33.59% | $46M |
| Q3 FY2025 | $115M | $117M | $5.68 | 47.58% | $13M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $268M | $124M | $6.13 | 17.61% | $49M |
| FY2024 | $167M | -$4M | -$0.22 | -13.53% | $77M |
| FY2023 | $131M | $52M | $2.94 | 9.09% | -$4M |
Frequently asked questions
What was Ligand Pharmaceuticals Incorporated's revenue last quarter?
Ligand Pharmaceuticals Incorporated reported revenue of $78.7 million for Q3 FY2026, down 31.8% from the same period a year earlier.
Is Ligand Pharmaceuticals Incorporated profitable?
Not in its most recent reported period. Ligand Pharmaceuticals Incorporated reported a net loss of $28.5 million for Q3 FY2026, a net margin of -36.17% on revenue.
How has Ligand Pharmaceuticals Incorporated's margin trended?
Operating margin was -20.01% in Q3 FY2026, compared with 47.58% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Ligand Pharmaceuticals Incorporated generate?
Ligand Pharmaceuticals Incorporated generated free cash flow of -$27.7 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Ligand Pharmaceuticals Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.